Get the Stockscreener App
1.79
3.47%
0.06
After Hours:
1.75
-0.04
-2.23%
Unity Biotechnology Inc stock is traded at $1.79, with a volume of 209.92K.
It is up +3.47% in the last 24 hours and up +86.50% over the past month.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
See More
Previous Close:
$1.73
Open:
$1.75
24h Volume:
209.92K
Relative Volume:
1.44
Market Cap:
$30.16M
Revenue:
-
Net Income/Loss:
$-52.53M
P/E Ratio:
-0.4891
EPS:
-3.66
Net Cash Flow:
$-39.93M
1W Performance:
+4.68%
1M Performance:
+86.50%
6M Performance:
+23.45%
1Y Performance:
+7.19%
1-Day Range:
$1.725
$1.84
1-Week Range:
$1.56
$1.84
52-Week Range:
$0.9397
$2.02
Unity Biotechnology Inc Stock (UBX) Company Profile
Name
Unity Biotechnology Inc
Sector
Industry
Phone
(650) 416-1192
Address
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Compare UBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
1.79 | 30.16M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-16-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-04-22 | Upgrade | ROTH Capital | Neutral → Buy |
| Nov-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Jun-28-21 | Upgrade | Citigroup | Sell → Buy |
| Jun-07-21 | Initiated | H.C. Wainwright | Buy |
| Feb-16-21 | Downgrade | Citigroup | Neutral → Sell |
| Aug-18-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-18-20 | Downgrade | Mizuho | Buy → Neutral |
| Aug-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-17-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-28-20 | Initiated | ROTH Capital | Buy |
| Dec-12-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Initiated | Mizuho | Buy |
| May-29-18 | Initiated | Citigroup | Buy |
| May-29-18 | Initiated | Goldman | Neutral |
| May-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Unity Biotechnology Inc Stock (UBX) Latest News
Research Analysts Offer Predictions for UBX FY2024 Earnings - Defense World
Geode Capital Management LLC Buys 14,199 Shares of Unity Biotechnology, Inc. (NASDAQ:UBX) - Defense World
Unity Biotechnology (NASDAQ:UBX) Coverage Initiated at Chardan Capital - Defense World
Chardan initiates Unity Biotechnology stock with Buy rating, cites senolytic UBX1325 potential - Investing.com India
Chardan Capital Initiates Coverage of Unity Biotechnology (UBX) with Buy Recommendation - MSN
UBXUnity Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
Unity Biotechnology (NASDAQ:UBX) Shares Down 26.5% – Here’s What Happened - Defense World
UNITY Biotechnology Reports Granting of New Employment Inducement Award - GlobeNewswire
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
UNITY Biotech appoints new chief medical officer - Investing.com
UNITY Biotech Appoints SYFOVRE Developer Dr. Grossi as CMO Ahead of Key DME Trial Results - StockTitan
Unity Biotechnology, Inc. (NASDAQ:UBX): Is Breakeven Near? - Simply Wall St
We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate - Yahoo Finance
Unity Biotechnology stock hits 52-week low at $0.94 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com India
Unity Biotechnology stock hits 52-week low at $0.95 By Investing.com - Investing.com Nigeria
Unity Biotechnology stock hits 52-week low at $0.95 - Investing.com
Unity Biotechnology (NASDAQ:UBX) Trading Down 5.6% – What’s Next? - Defense World
Unity Biotechnology stock hits 52-week low at $1.1 - Investing.com
Unity Biotechnology stock hits 52-week low at $1.1 By Investing.com - Investing.com UK
Unity Biotechnology stock hits 52-week low at $1.1 amid challenges - Investing.com Canada
Unity Biotechnology (FRA:9U90) EV-to-Revenue : (As of Dec. 05, 2024) - GuruFocus.com
Unity Biotechnology (STU:9U90) EV-to-Revenue : (As of Nov. 28, 2024) - GuruFocus.com
Finance Watch: Adcendo Pursues Proof-Of-Concept With $135m Series B Round - Citeline
Unity Biotechnology (FRA:9U90) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors - BioSpace
Alyeska Investment Group L.P.'s Strategic Acquisition in Unity B - GuruFocus.com
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Unity Biotechnology's CFO sells shares worth $175 - Investing.com India
Unity Biotechnology's chief legal officer sells shares worth $192 - Investing.com India
Unity Biotechnology's CFO sells shares worth $175 By Investing.com - Investing.com Canada
Unity Biotechnology's chief legal officer sells shares worth $192 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $1.15 - Investing.com
Unity Biotechnology CEO Anirvan Ghosh sells $557 in stock - Investing.com
Unity Biotechnology stock hits 52-week low at $1.15 By Investing.com - Investing.com Canada
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth? - Simply Wall St
Unity Biotechnology Focuses on Promising DME Treatment - TipRanks
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Age-related Macular Degeneration Market Size is Set for Rapid - openPR
Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals - Yahoo Finance UK
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times
Unity Biotechnology Inc Stock (UBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):